Clinical Trials on Advanced NSCLC

Total 6631 results

EQRx International, Inc.

Terminated

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NSCLC

United States
The First Affiliated Hospital of Zhengzhou University

Active, not recruiting

Tislelizumab in Addition to BACE in Patients With NSCLC

NSCLC

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

NSCLC

China
Yonsei University

Completed

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

NSCLC
Samsung Medical Center

Unknown

Afatinib Plus Nimotuzumb for NSCLC

NSCLC

Korea, Republic of
University of Alabama at Birmingham
Sanofi

Completed

Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC) | Metastatic NSCLC | Stage IV NSCLC

United States
Joel Neal
Nektar Therapeutics

Completed

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Tumors Metastatic to Brain | Stage IV Non-small Cell Lung Cancer (NSCLC) | Recurrent Non-small Cell Lung Cancer (NSCLC) | Extensive-stage Small Cell Lung Cancer (SCLC) | Recurrent Small Cell Lung Cancer (SCLC) | Metastatic Breast Cancer (mBC)

United States
ImmVira Pharma Co. Ltd

Recruiting

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

Sarcoma | Breast Cancer | NSCLC | Advanced Solid Tumor | HNSCC | Esophagus Cancer | Non-melanoma Skin Cancer

China
Chao Huang
University of Kansas Medical Center

Active, not recruiting

Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

Advanced Solid Tumor | Non-small Cell Lung Cancer (NSCLC)

United States
Daiichi Sankyo, Inc.

Completed

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

NSCLC (Advanced Non-small Cell Lung Cancer)

Ukraine, United Kingdom, United States, Bulgaria, Belgium, Germany, Hungary, Austria, Italy, Israel, Lithuania, Romania, Slovenia
Daiichi Sankyo, Inc.

Completed

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, India, Germany
Taixing People's Hospital

Recruiting

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

NSCLC

China
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

99mTc-H7ND SPECT/CT Imaging in NSCLC

NSCLC

China
Xuhua Duan

Recruiting

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

NSCLC

China
The First Affiliated Hospital of Henan University...

Not yet recruiting

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

NSCLC
Exactis Innovation

Recruiting

An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network

NSCLC

Canada
Maastricht Radiation Oncology
AstraZeneca; Dutch Society of Physicians for Pulmonology and Tuberculosis; Erasmus... and other collaborators

Recruiting

Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy (ELDAPT)

NSCLC

Netherlands
Guangzhou Institute of Respiratory Disease

Completed

Whether Sputum Can Serve as an Alternative Source for Liquid Biopsy in Patients With Lung Cancer

NSCLC

China
The Netherlands Cancer Institute
AstraZeneca

Completed

Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC (olaparib)

NSCLC

Netherlands
Xinqiao Hospital of Chongqing

Completed

The Correlation of PD-L1 Expression in Non-small Lung Cancer Tissue and Peripheral Blood T Cell and Serum.

NSCLC

China
The Netherlands Cancer Institute

Completed

PET Response During Chemoradiation of Lung Cancer

NSCLC

Netherlands
Yonsei University

Withdrawn

Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation

NSCLC
Shenzhen Hornetcorn Bio-technology Company, LTD

Unknown

Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients

NSCLC

China
Severance Hospital
AstraZeneca

Unknown

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

NSCLC
Suzhou Puhe Pharmaceutical Technology Co., LTD

Not yet recruiting

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

China
Takeda

Active, not recruiting

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, France, Korea, Republic of, Hong Kong, Australia, Taiwan, United Kingdom, Canada, Turkey, Italy, China, Germany, Japan, Austria, Belgium, Greece, Israel, Netherlands, Portugal, Russian Federation, Singapore, Sw... and more
Aprea Therapeutics

Completed

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Gastric Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Urothelial Carcinoma

United States
Shanghai JMT-Bio Inc.

Active, not recruiting

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Local Advanced or Metastatic NSCLC | Harboring EGFR Common Mutation

China
Fujian Cancer Hospital

Not yet recruiting

Almonertinib Plus Metronomic Oral Vinorelbine

NSCLC | EGFR | Third-generation TKI
Lady Davis Institute

Withdrawn

Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients (CH:II)

Metastatic NSCLC

Canada
Tongji University

Recruiting

A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

NSCLC, Stage IIIA | EGF-R Negative Non-Small Cell Lung Cancer | ALK Negative NSCLC

China
National Cancer Institute (NCI)

Recruiting

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Adenocarcinoma | Advanced Non-Small Cell Lung Cancer | Squamous Cell Carcinoma | Advanced NSCLC | Adenosquamous Carcinoma

United States
Tiziana Life Sciences LTD

Not yet recruiting

Milciclib in Combination With Gemcitabine in Advanced NSCLC

NSCLC
Akeso

Recruiting

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

NSCLC

China
Shanghai Chest Hospital

Not yet recruiting

A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. (CAMFA-L)

NSCLC

China
Allist Pharmaceuticals, Inc.

Recruiting

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation (FAVOUR)

NSCLC

China
Olfred Hansen
Odense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Herlev Hospital and other collaborators

Recruiting

Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®

NSCLC

Denmark
Xinqiao Hospital of Chongqing

Completed

Consistency Analysis of PD-L1s in Advanced NSCLC Tissues and in Plasma Exosomes Before and After Radiotherapy (RadImm02)

NSCLC

China
InventisBio Co., Ltd

Active, not recruiting

Study to Evaluate D-1553 in Subjects With Lung Cancer

NSCLC

China
Allist Pharmaceuticals, Inc.

Withdrawn

Phase Ib Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

NSCLC

China
Klinikum Bayreuth GmbH
Peking University Cancer Hospital & Institute; Sana Klinikum Hof

Completed

Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma (PANU)

NSCLC
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield; Weston Park Hospital Cancer Charity; Sheffield Hospitals...

Completed

Lung HeXeRT: Helium, Xenon MRI for NSCLC Patients (HeXeRT)

NSCLC

United Kingdom
Fudan University

Completed

Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC

NSCLC

China
Sun Yat-sen University

Unknown

S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC

NSCLC

China
Chang Gung Memorial Hospital

Unknown

Circulating Fibrocytes in Non-small Cell Lung Cancer.

NSCLC

Taiwan
Bai Jun

Unknown

Gefitinib Combined With Thalidomide to Treat NSCLC

NSCLC
Qianfoshan Hospital

Recruiting

Patient's Whole Process Follow-up Management(HOPE-1) (HOPE-1)

Metastatic NSCLC | Locally Advanced Non-Small Cell Lung Cancer

China
AbbVie

Active, not recruiting

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Advanced Solid Tumors Cancer | Non Small Cell Lung Cancer (NSCLC)

United States, Australia, France, Israel, Japan, Korea, Republic of, Spain, Taiwan
Bristol-Myers Squibb

Completed

Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer

Lung Cancer | Non-small Cell Lung Cancer NSCLC | Small Cell Lung Cancer SCLC

China
Kyowa Kirin Korea Co., Ltd.

Terminated

Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma | Phase 2 Portion : Small Cell Lung Cancer(SCLC)

Korea, Republic of

Clinical Trials on Advanced NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations